Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?

View ORCID ProfileAnne M. Sydor, Emily Bergin, Jonathan Kay, Erik Stone, View ORCID ProfileRobert Popovian
doi: https://doi.org/10.1101/2023.10.31.23297782
Anne M. Sydor
1Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne M. Sydor
Emily Bergin
1Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Kay
1Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Stone
1Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Popovian
1Division of Patient-Focused Economic and Policy Research, Global Healthy Living Foundation, Upper Nyack NY, United States
2Pioneer Institute, Boston MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Popovian
  • For correspondence: rpopovian{at}ghlf.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Drug formularies, initially designed to promote the use of cost-effective generic drugs are now designed to maximize financial benefits for the pharmacy benefit management companies that negotiate drug purchase prices. In the largest publicly available formulary, 55% of mandated substitutions are not for generic versions of the same active ingredient and/or formulation and may not be medically or financially beneficial to patients.

Methods We modeled the effect of excluding novel agents for atrial fibrillation/venous thromboembolism, migraine prevention, and psoriasis, which all would require substitution with a different active ingredient. Using population data, market share of the two largest U.S. formularies, and 2021 prescription data, we calculated how many people could be affected by such exclusions. Using data from the published literature, we calculated how many of those individuals are likely to discontinue treatment and/or have adverse events due to a formulary exclusion.

Results The number of people likely to have adverse events due to the exclusion could be as high as one million for atrial fibrillation/venous thromboembolism, 900,000 for migraine prevention, and 500,000 for psoriasis. The numbers likely to discontinue treatment for their condition are as high as 924,000 for atrial fibrillation/venous thromboembolism, 646,000 for migraine, and 138,000 for psoriasis.

Conclusion Substitution with a nonequivalent treatment is common in formularies currently in use and is not without substantial consequences for hundreds of thousands of patients. Forced drug substitution results in costly increases in morbidity and mortality and should be part of the cost-benefit analysis of any formulary exclusion.

Competing Interest Statement

Robert Popovian is the founder of Conquest Advisors, LLC, owns stocks of biopharmaceutical companies, and was an employee of Pfizer for over two decades. He is a member of the Board of Councilors, University of Southern California, School of Pharmacy, Board of Directors, for University Pharmaco, LLC, Adjunct Clinical Faculty at Rutgers University, School of Pharmacy and serves as a consultant for the biopharmaceutical industry. The authors declare no other relevant conflicts of interest or financial relationships.

Funding Statement

This study was funded by unrestricted educational grants from Amgen and Pfizer.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • COMPETING INTERESTS DISCLOSURE: Robert Popovian is the founder of Conquest Advisors, LLC, owns stocks of biopharmaceutical companies, and was an employee of Pfizer for over two decades. He is a member of the Board of Councilors, University of Southern California, School of Pharmacy, Board of Directors, for University Pharmaco, LLC, Adjunct Clinical Faculty at Rutgers University, School of Pharmacy and serves as a consultant for the biopharmaceutical industry. The authors declare no other relevant conflicts of interest or financial relationships.

  • FUNDING: This modeling study was funded by unrestricted educational grants from Amgen and Pfizer.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 07, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?
Anne M. Sydor, Emily Bergin, Jonathan Kay, Erik Stone, Robert Popovian
medRxiv 2023.10.31.23297782; doi: https://doi.org/10.1101/2023.10.31.23297782
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?
Anne M. Sydor, Emily Bergin, Jonathan Kay, Erik Stone, Robert Popovian
medRxiv 2023.10.31.23297782; doi: https://doi.org/10.1101/2023.10.31.23297782

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)